期刊文献+

反相高效液相色谱法检测小鼠血浆中FG020326方法的建立 被引量:5

A method for determining the concentration of FG020326 in mice plasma by RP-HPLC
下载PDF
导出
摘要 目的建立测定多药耐药(multidrug resistance,MDR)逆转剂FG020326在KM小鼠血浆中血药浓度的方法。方法将KM小鼠(20.0~25.1)g随机分组,每组6只,♀♂各半,尾静脉注射,给药量为30mg·kg^-1,分时取血、处理。采用反相色谱柱,应用外标法测定FG020326在KM小鼠血浆中的血药浓度。结果在所建立的方法学下,FG020326的保留时间为7.9min;标准曲线为·↑Y=0.0144X-0.0285(r=0.9998),在162.5~41600μg·L^-1血浆浓度范围内呈良好的线性关系,最低检测浓度40μg·L^-1(S/N=3);在650、2600、20800μg·L^-1低、中、高3个浓度下的绝对回收率为68.66%~84.63%,相对回收率为92.58%~110.88%;日内及日间RSD均小于3.2%(n=5)。在室温及冷冻-解冻试验中,FG020326具有良好的稳定性,RSD分别小于1.3%和6.0%。尾静脉单次给药后,FG020326在体内过程符合二室模型,T1/2α为0.088h,T1/2β为5.33h,AUC0-∝。为14183h·μg·L^-1,Vd为0.37L。结论该方法快速、准确、简便,能够满足FG020326药代动力学研究要求。 Aim To establish a method to determine the concentration of FG020326 in the plasma of KM mice by reverse phase high-performance liquid chromatography. Methods KM mice were used throughout the experiment and their body weights ranged from 20. 0 to 25. 1 g. All of them were distributed randomly to different test groups which each had 6 mice. FG020326 was administered at a dose of 30 mg · kg^-1 via tail vein. The external standard method was used for the quantitation of FG020326. Results Under the condition of HPLC, the retention time of FG020326 was 7. 9 min. The standard curve was ·↑Y = 0. 0144X - 0. 0285 ( r = 0. 9998 ) with a validated quantitation range of 162.5~4 1600μg · L^-1, and the lowest concentration of detection in mice plasma was 40μg · L^-1( S/N = 3 ). At the concentration of 650,2 600,20 800 μg · L^-1, absolute recovery rates were ranged from 68.66% to 84. 63% and relative recovery rates were ranged from 92.58% to 110. 88%. The RSD of the precision within-day and between-day were less than 3.2%. At ambient temperature and four freeze-thaw cycles, FG020326 was stable and the RSD was less than 1.3% and 6.0%, respectively. The concentration-time curve of FG020326 was well fitted to a two-compartment model. T1/2α and T1/2β were 0. 088 h and 5.33 h, respectively. AUC0→∞ was 14 183 h·μg·L^-1 and Vd was 0. 37 L. Conclusion The assay method is shown to be sensitive, suitable and accurate for determination of FG020326 in mice plasma.
出处 《中国药理学通报》 CAS CSCD 北大核心 2007年第1期131-134,共4页 Chinese Pharmacological Bulletin
基金 国家自然科学基金资助课题(No30371659)
关键词 FG020326 药代动力学 反相高效液相色谱 多药耐药 FG020326 pharmacokinetics RP-HPLC MDR
  • 相关文献

参考文献9

  • 1Chen L M,Liang Y J,Fu L W,et al.Screening novel,potent multidrug-resistant modulators from imidazole derivatives[J].Oncol Res,2004,14(7-8):355-62.
  • 2Chen L M,Gu L Q,Fu L W,et al.Reversal of P-gp mediated multidrug resistance in vitro and in vivo by FG020318[J].J Pharm Pharmacol,2004,56(8):1061-6.
  • 3王秀文,丁岩,梁永钜,陈黎明,石智,杨小平,古练权,符立梧.FG020326通过增加泰素帝介导caspase-8和3激活的敏感性克服多药耐药细胞MCF-7/ADR的凋亡抗性[J].癌症,2004,23(z1):1379-1385. 被引量:10
  • 4戴春岭,符立梧.肿瘤多药耐药逆转剂的研究进展[J].中国药理学通报,2005,21(5):513-518. 被引量:39
  • 5Bates S E,Bakke S,Kang M,et al.A phaseⅠ/Ⅱstudy of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC833) in renal cell carcinoma[J].Clin Cancer Res,2004,10(14):4724-33.
  • 6Minderman H,O'Loughlin K L,Pendyala L,et al.VX-710(biricodar)increasea drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein,multidrug resistance protein,and breast cancer resistance protein[J].Clin Cancer Res,2004,10(5):1826-34.
  • 7Sandler A,Gordon M,De Alwis D P,et al.De A Phase Ⅰ trial of a potent P-glycoprotein inhibitor,zosuquidar trihydrochloride (LY335979),administered intravenously in combination with doxorubicin in patients with advanced malignancy[J].Clin Cancer Res,2004,10(10):3265-72.
  • 8Newman M J,Rodarte J C,Benbatoul K D,et al.Discovery and characterization of OC144-093,a novel inhibitor of P-glycoprotein-mediated multidrug resistance[J].Cancer Res,2000,60(11):2964-72.
  • 9Guns E S,Denyssevych T,Dixon R,et al.Drug interaction studies between paclitaxel (Taxol) and OC144-093-a new modulator of MDR in cancer chemotherapy[J].Eur J Drug Metab Pharmacokinet,2002,27(2):119-26.

二级参考文献40

  • 1[1]Hanahan D, Weinberg RA. The hallmarks of cancer [J] . Cell,2000, 100:57 - 70.
  • 2[2]Kim R, Tanabe K, Uehida Y, et al. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy [J]. Cancer Chemother Pharmacol, 2002, 50 (5): 343 - 352.
  • 3[3]Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspaseindependent, cell death [J]. Blood, 1999, 93(3): 1075 - 1085.
  • 4[4]Ruefli AA, Smyth MJ, Johnstone RW. HMBA induces activation of a P-glycoproteinmediated multidrug resistance [J]. Blood, 2000,95:2378 - 2385.
  • 5[5]Campone M, Vavasseur F, Le Cabellec MT, et al. Induction of chemoresistance in HL-60 cells concomitantly causes a resistance to apoptosis and the synthesis of P-glycoprotein [J]. Leukemia,2001, 15(9): 1377 - 1387.
  • 6[6]Shtil AA, Grinchuk TM, Tee L, et al. Overexpression of P-glycoprotein is associated with a decreased mitochondrial transmembrane potential in doxorubicin-selected K562 human leukemia cells [J]. Int J Oncol, 2000, 17:387 - 392.
  • 7[7]Chen LM, Wu XP, Ruan JW, et al. Screening novel, potent multidrug-resistant modulators from imidazole derivatives [J].Oncol Res, 2004, 14(7-8): 355 - 362.
  • 8[8]Chen LM, Liang YJ, Ruan JW, et al. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318 [J] . J Pharm Pharmacol, 2004, 56 (8): 1061 - 1066.
  • 9[9]Fu L, Liang Y, Deng L, et al. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance [J].Cancer Chemother Pharmacol, 2004, 53 (4): 349 - 356.
  • 10[10]Tolomeo M, Simoni D. Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies [J]. Curr Med Chem Anti-Canc Agents, 2002, 2 (3): 387 -401.

共引文献47

同被引文献31

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部